Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 plus gemcitabine versus placebo plus gemcitabine in first-line metastatic pancreatic adenocarcinoma
NL-OMON38111Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ganitumab in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Amgen. Primary endpoint: Overall survival. Started Apr 2012; status: active, not recruiting.
02
Drugs
ganitumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON38111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38111.